Role of lymphopenia and inflammation in COVID-19 pathogenesis

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications, trials & patents

Abstract

In order to evaluate the pathogenesis of COVID with a focus on lymphopenia, inflammation and coagulopathy, we have opened a protocol to obtain clinical samples (peripheral blood mononuclear cells, serum and plasma, nasal swabs) from people with active COVID-19 disease. In addition, recovered patients may enroll and have a similar sample collection for comparison purposes. As part of our hypothesis that lymphopenia and lack of robust adaptive responses are associated with poor prognosis we also established a dose-escalation phase I study (pilot) of long acting IL-7 in people with early mild disease.